| INTRODUCTION
Enterocutaneous fistula (ECF) and enterostomies both can cause intestinal failure due to high fluid, nutrient and electrolyte losses, and medical treatment is a challenge. Intestinal failure (IF) is defined as the inability of the intestinal tract to maintain protein/energy, fluid, electrolyte or micronutrient balance resulting in the need for intravenous (iv) fluid supplementation and/or total parenteral nutrition (TPN). [1] [2] [3] In most cases, this is due to a high-output ECF or enterostomy. Although different definitions are used in literature, [4] [5] [6] [7] generally an ECF producing over 500 mL/24 h or an enterostomy producing over 1500 mL/24 h is considered as high output. Three types of intestinal failure can be distinguished. Type 1 acute IF is self-limiting and common following abdominal surgery, and the necessity of iv fluid and nutritional support is short (<28 days). Type
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2 IF is also acute in onset and reversible, but requires >28 days of iv fluid and/or nutritional support and is often associated with septic, metabolic and complex nutritional complications. Finally, type 3 IF is characterised as chronic IF, frequently irreversible and requires long term or even lifelong therapy with iv fluid and/or TPN. [1] [2] [3] Generally, type 2 IF is reversible after adequate treatment of abdominal infections/sepsis and full recovery of the patient followed by reconstructive surgery. However, it is recommended to postpone surgery for several months to ensure that the patient and the abdominal cavity are in optimal condition for surgery. 8, 9 In all types of IF, medication is frequently needed in the short and/or long term to reduce output of an enterostomy or fistula. In theory, by reducing output, the need for artificial nutritional support, the occurrence of dehydration, electrolyte losses, weight loss, and leakage can be prevented or better managed and, if effective, may lead to fewer hospital admissions, lower complication rates and better quality of life. Two categories of medication can be distinguished; medication that prolongs intestinal transit time, and medication that reduces gastro-intestinal (hyper-) secretion. 10 We briefly summarised different types of available medication, their pharmacokinetics and potential side effects in Table 1 .
To date, there is no generally accepted standardised protocol to reduce output in patients with (high-output) enterocutaneous fistulas or enterostomies and treatment is mostly expert opinion based. A clear overview of published studies on output reduction is lacking.
Our primary aim was to systematically review the literature on pharmacological interventions to reduce ECF or enterostomy output.
Second, we aimed to present an algorithm for standard of care for output reduction in the acute phase in patients with IF based on the findings of this review and our experience in a national referral centre for intestinal failure. To make the algorithm widely applicable, reviewing literature on medication enhancing bowel adaptation in patients with chronic intestinal failure was not within the scope of the present review.
| METHODS
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 11 guidelines were followed up for conducting this systematic review.
| Literature search
A systematic search on pharmacological interventions to reduce output in patients with either enterocutaneous fistulas or enterostomies was performed on January 27th, 2016. A clinical librarian was consulted to optimise the search strategy. Medline (PubMed), EMBASE (Ovid), and the Cochrane Library were searched to identify studies on the subject. Our search terms consisted of different definitions for enterocutaneous fistulas and enterostomies combined with known medication used in the treatment of output reduction. The full search is included in Appendix S1. Two authors (FdV and LR)
independently assessed all titles and abstracts. Relevant articles were assessed for full text. Disagreement on the inclusion of the studies was resolved through discussion and consensus. References of the included studies were screened for other relevant studies.
| Study selection/inclusion and exclusion criteria
Randomised controlled trials (RCT) and within-patient controlled prospective trials performed in adult patients with either (high-output) enterocutaneous fistulas (small bowel or colon) or enterostomies, were included. The studies had to report output reduction compared with either baseline output, placebo or a comparator.
Studies including less than five subjects, animal studies, studies on medication to manipulate bowel adaptation in chronic intestinal failure, studies on medication to prevent bacterial overgrowth and 12 and with the Newcastle-Ottawa scale 13 for non-randomised controlled trials by two authors (FdV and LR). Disagreement on data extraction and risk of bias assessment was resolved through discussion and consensus.
| RESULTS
The initial search in Medline (PubMed), EMBASE (Ovid), and the Cochrane library identified 1633 articles. After screening titles and abstracts, 36 articles were selected for full text reading. Seventeen of these 36 studies were excluded for the following reasons; seven did not report on output reduction as outcome, six were retrospective cohort series, three studies reported on less than five patients and one was an editorial comment. One additional study 14 was identified through cross-referencing included studies and included in this report. A flow chart of the search is presented in Figure 1 .
A total of 20 studies (13 RCTs 14-26 and seven within-patient controlled prospective (cross-over studies) [27] [28] [29] [30] [31] [32] [33] ) were included. All Table S1 .
| Quality of the included studies
The results of the quality assessment of all studies are shown in Tables S2 and S3 . Overall quality was moderate to low.
| Output reduction 3.2.1 | Proton pump inhibitors
One RCT 26 and one within-patient controlled study 27 have examined the effect of proton pump inhibitors (PPIs) on output reduction.
Jeppesen et al. 26 performed a cross-over study with a PPI (omeprazole 40 mg twice a day intravenously [iv] ) and a histamine receptor antagonist (ranitidine 150 iv) in random order. Both drugs significantly decreased stoma output (P=.001) compared with a short control period at the end of the study but iv omeprazole was superior to ranitidine. Nightingale et al. 27 showed a significant output reduction in patients with omeprazole 40 mg orally compared to baseline.
Both studies did not mention any adverse events.
| Anti-motility agents
Four RCTs and two within-patient controlled studies have reported on anti-motility agents in patients with an ileo-or a colostomy. Four studies on loperamide [16] [17] [18] 29 showed a significant effect on output reduction. Mean or median output reduction in the individual studies varied between 22% and 45%. The used dosage varied between a single dose of 6 mg and 4 times a day 4 mg. One study, 15 comparing both loperamide and codeine with a placebo, found a significant reduction in output for both drugs. However, loperamide is more effective and has fewer side effects compared with codeine. Another within-patient controlled study 28 on codeine, diphenoxylate and isogel found a significant effect of codeine phosphate on output reduction, but no significant effect of diphenoxylate or isogel. Both studies used a maximum of 60 mg codeine a day.
| Histamine-2 receptor antagonists
Two RCTs 14, 26 and two within-patient controlled studies 30, 31 have examined the effect of histamine receptor antagonists. Jeppesen et al. 26 reported a significant effect of ranitidine 150 mg iv on output reduction (P=.001) (omeprazole results are mentioned above).
Two within-patient controlled trials 30, 31 and one RCT 14 (compared with placebo) on cimetidine all found a significant output reduction.
These studies used both oral and iv administration and a dosage varying from 200 to 800 mg a day.
| a2-receptor agonists
Buchmann et al. 32 have studied the effect of a clonidine patch on output reduction in a within patient controlled prospective trial and found no significant benefit of clonidine on volume output.
| Somatostatin (analogues)
Eight trials (seven RCTs [19] [20] [21] [22] [23] [24] [25] and one within-patient controlled study 33 ) have studied the effect of somatostatin (analogues) on output reduction in subjects with either small bowel enterostomies or enterocutaneous fistulas. Four studies 19, [23] [24] [25] (three using octreotide and one using somatostatin, two in patients with ECF and two in patients with an enterostomy) showed a significant effect on output reduction. Another study of Gayral et al., 22 which also included pancreatic fistulas, found an overall significant effect in reaching 50% output reduction when using sandostatine, a long-acting release depot of octreotide, but failed to show this effect in a subgroup analysis of duodenal and small bowel fistulas (P=.184). Two RCTs 20,21 have compared octreotide with placebo and found no significant effect on ECF output reduction. One within-patient controlled prospective trial 33 showed no effect of sandostatine in patients with small bowel syndrome. Different medication (eg, somatostatin, octreotide, lanreotide) and dosages have been used in these studies (Table S1 ).
| Overall
The overall available evidence for treatments to reduce stoma and fistula output is summarised in Table 2 . Although an RCT can be considered level 1b evidence according to the Oxford Centre for Evidencebased Medicine, the majority of RCTs did not provide a sample size calculation (only Gayral et al. 22 and Sancho et al. 20 did provide a sample size calculation), had wide confidence intervals or were of low quality. Therefore, we considered them level 2b of evidence. The present algorithm is aimed at maximum reduction in output with minimal side effects. We target to reduce fistula output to less than 500 mL/24 h and stoma output to less than 1500 mL/24 h. However, in patients with a very proximal fistula or an ultra-short bowel this is often not achievable and lowering output as much as possible should be the aim for that specific group of patients. We combine this algorithm with a fluid restriction of 500-1000 mL isotonic drinks 35 and a short-bowel diet according to the ESPEN guidlines. 36 Unfortunately, there is limited evidence on isotonic and hypotonic solutions in patients with high-output fistulas or enterostomies. 35 We aim to have a minimum urine output of at least 1 L. and the superior effect of loperamide in the study of King et al. 15 Due to intestinal resorption of codeine, it is important to start at a low dose (three times a day 10 mg) and increase the dosage up to Most studies on somatostatin (analogues) were performed to assess the effect on fistula closure rather than output reduction.
Three recent systematic reviews and meta-analyses 38-40 on somatostatin (analogues) and ECF showed a potential benefit in time to closure and closure rate. However, this effect is most likely to be found in simple low-output fistulas. Chances of spontaneous fistula closure in highly productive complex fistulas are extremely low. 41, 42 Furthermore, the evidence that reducing output from these fistula would increase the chance of spontaneous closure is not convincing. 43 Recent evidence 22 on the effect of somatostatin analogues on gastro-intestinal fistula might be biased by inclusion of subjects with pancreatic fistulas (in that study >50%). A subgroup analysis of the subjects with duodenal and small bowel fistulas did not reveal a benefit for output reduction in contrast with the study's overall outcome. Moreover, the studies of Torres et al. 19 and Nubiola et al., 23 who did find a beneficial effect of somatostatin analogues on output reduction, included simple, single tract fistulas only. Therefore, we question whether the effect on output reduction as described for somatostatin analogues in pancreatic fistulas or simple fistulas can be extrapolated to high-output complex fistulas. In our opinion, high- and chronic intestinal failure, we here propose an algorithm for standard of care in these mostly complex patients. We have systemically implemented this algorithm in our patient care and found no major side effects and are currently monitoring effectiveness.
The combined use of different categories of medication proposed in the present algorithm is based on the available evidence, clinical expertise, side effects and costs. Omeprazole, cimetidine, and ranitidine all reduce gastro-intestinal secretion. 44 However, both cimetidine and ranitidine were replaced by PPIs as first choice treatment in most countries for other indications (symptom relief for reflux disease, treatment of gastric/duodenal ulcers and in reducing mortality, re-bleeding and surgical interventions for upper gastrointestinal bleeding) with comparable side effects [44] [45] [46] [47] making it a more logical choice than cimetidine or ranitidine. Moreover, the study of Jeppesen 26 showed that omeprazole was superior to ranitidine. However, PPI use is associated with severe hypomagnesemia, 48 an electrolyte disorder frequently encountered in patients with highoutput fistula, enterostomies or short bowel syndrome. Therefore, in case of therapy refractory hypomagnesemia, PPI's can be replaced by a H2 receptor antagonist.
If we compare the present algorithm with other published articles or protocols on this topic, 5, 6, 10, 43, [49] [50] [51] we find that none of the articles systematically reviewed all available literature and only a few describe a step by step approach including medication dosing.
5,6
Both Baker et al. 6 and Villafranca et al. and are currently evaluating this algorithm. They contributed to writing the manuscript. GD and JH are the specialised intestinal failure gastroenterologist and surgeon of the UMCG. They contributed to the study design, data interpretation and writing the manuscript. MB and MS are the specialised intestinal failure surgeon and endocrinologist of the AMC respectively. They were involved in the study design and contributed to data interpretation and writing the manuscript.
All authors approved the final version of the article, including the authorship list.
R E F E R E N C E S

